Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26,019,256
-
Total 13F shares
-
6,739,020
-
Share change
-
-626,707
-
Total reported value
-
$11,187,178
-
Price per share
-
$1.66
-
Number of holders
-
18
-
Value change
-
-$1,098,483
-
Number of buys
-
8
-
Number of sells
-
8
Institutional Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q1 2023
As of 31 Mar 2023,
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,739,020 shares.
The largest 10 holders included
Novo Holdings A/S, Redmile Group, LLC, Bruce & Co., Inc., AXA S.A., Artal Group S.A., SILVERARC CAPITAL MANAGEMENT, LLC, Alpha Wave Global, LP, CANTOR FITZGERALD, L. P., PNC Financial Services Group, Inc., and BANK OF AMERICA CORP /DE/.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.